| 4 cohorts | 3 cohorts (French cohort excluded) | French cohort | French/other 3 cohorts | ||||||
---|---|---|---|---|---|---|---|---|---|---|
OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value | OR_F/OR_3cohorts | |
All internal tumors | 34 | 25–47 | 1.0E−47 | 21 | 13–35 | 4.9E−16 | 56 | 37–84 | 3.6E−35 | 2.64 |
CNS | 331 | 171–641 | 2.4E−20 | 371 | 165–834 | 2.7E−14 | 272 | 87–853 | 2.3E−07 | 0.73 |
HEM | 120 | 77–186 | 3.7E−36 | 37 | 14–99 | 5.4E−06 | 253 | 154–418 | 7.5E−35 | 6.84 |
THY | 74 | 31–179 | 1.2E−08 | 49 | 12–199 | 8.1E−04 | 111 | 35–346 | 3.4E−06 | 2.24 |
FEM* | 91 | 42–193 | 3.5E−12 | 50 | 6–187 | 8.0E−4 | 135 | 53–329 | 6.9E−10 | 2.7 |
MAL* | 9 | 1.3–69 | 0.10 | – | – | – | 10 | 0.24–55 | 0.1 | – |
Age 0–20 | 665 | 368–1200 | 4.3E−30 | 266 | 84–841 | 2.5E−07 | 1330 | 654–2701 | 1.9E−25 | 5.00 |
Age 21–40 | 234 | 153–358 | 1.5E−47 | 132 | 64–271 | 6.0E−15 | 381 | 221–655 | 2.6E−35 | 2.89 |
Age 41–60 | 22 | 8–60 | 4.8E−05 | 25 | 8–82 | 3.0E−04 | 16 | 2–116 | 6.5E−02 | 0.62 |
Age 61–80 | 7 | 2–30 | 3.6E−02 | 10 | 2–44 | 1.9E−02 | – | – | – | – |
XP-C | 64 | 45–90 | 3.9E−54 | 42 | 24–74 | 3.9E−18 | 90 | 58–140 | 1.6E−38 | 2.13 |
XP-E | 36 | 5–281 | 3.1E−02 | 46 | 6–372 | 2.5E−02 | – | – | – | – |
XP-V | 11 | 3–47 | 1.4E−02 | 12 | 2–91 | 8.1E−02 | 11 | 1–78 | 9.2E−02 | 0.87 |